DT (18) treatment resulted in decreased expression of CCL2 and C-X-C motif chemokine ligand 1 (CXCL1) and increased expression of IL-8, blocking the ability of macrophages to promote lung cancer cell migration and the recruitment of macrophages by lung cancer cells. Here, CXCL1 is linked to lung cancer.